Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells
Anna Parente-Ribes,
Sigrid S. Skånland,
Simone Bürgler,
Audun Os,
Dong Wang,
Bjarne Bogen,
Geir E. Tjønnfjord,
Kjetil Taskén,
Ludvig A. Munthe
Affiliations
Anna Parente-Ribes
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway
Sigrid S. Skånland
Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Norway;Biotechnology Centre, K. G. Jebsen Centre for Inflammation Research and K. G. Jebsen Centre for Cancer Immunotherapy, University of Oslo, Norway
Simone Bürgler
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway;Department for Haematology, Oslo University Hospital, Rikshospitalet, Oslo & Institute of Clinical Medicine, University of Oslo, Norway
Audun Os
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway
Dong Wang
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway
Bjarne Bogen
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway;KG Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo, Norway
Geir E. Tjønnfjord
Department for Haematology, Oslo University Hospital, Rikshospitalet, Oslo & Institute of Clinical Medicine, University of Oslo, Norway
Kjetil Taskén
Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Norway;Biotechnology Centre, K. G. Jebsen Centre for Inflammation Research and K. G. Jebsen Centre for Cancer Immunotherapy, University of Oslo, Norway;Department of Infectious Diseases, Oslo University Hospital, Norway
Ludvig A. Munthe
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway
